X. Yu - Zhejiang Canc Hosp | 人才画像

基本信息

浏览量：8

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 58 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Nivolumab Plus Ipilimumab Vs Chemotherapy in Patients with Stage IV/recurrent NSCLC and PD-L1 ≥ in China: Checkmate 227 CHESS

Y. L. Wu, X. Wu,K. Ying, G. Chen, Z. Wang, W. Lin,S. Lu,H. Zhong,Y. Cheng,J. Cui, M. Wang, K. Wang,B. Zhu,X. Yu, Y. Chen, C. Liu,Y. Yao, H. Sun, S. Wang,M. Tschaika,M. Pe Benito, A. Lee, Y. Yuan,L. Wu

JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S97-S98

引用0浏览0引用

AB0051 THE ASSOCIATION BETWEEN COVID-19 INFECTION AND DISEASE FLARES IN PATIENTS WITH BEHÇET’S SYNDROME

Zheng W., Liu Y., Wang Z.,Yu X.,Liu J.

Annals of the Rheumatic Diseases (2024): 1252-1253

引用0浏览0引用

MA11.05 Nivolumab + Ipilimumab Vs Chemotherapy in Patients with Stage IV/recurrent NSCLC and PD-L1 ≥ in China: Checkmate 227 CHESS

Y.-L. Wu, X. Wu,K. Ying, G. Chen, Z. Wang, W. Lin,S. Lu,H. Zhong,Y. Cheng,J. Cui, M. Wang, K. Wang,B. Zhu,X. Yu, Y. Chen, C. Liu,Y. Yao, H. Sun, S. Wang,M. Tschaika

Journal of Thoracic Oncologyno. 10 (2024): S97-S98

引用0浏览0引用

497P Sintilimab in Combination with Anlotinib in Advanced NSCLC Treated with First-Line PD-1 Antibodies: an Open, Single-Arm, Phase II Trial

Y. Jin,X. Yu,Y. Fan, X. Q. He, C. Lin,W. Hong, C. Gu

Annals of Oncology（2023）

引用0浏览0引用

Nivolumab Plus Chemotherapy in First-Line Metastatic Non-Small-cell Lung Cancer: Results of the Phase III CheckMate 227 Part 2 Trial

H. Borghaeit, K. J. O'Byrnet,L. Paz-Ares,T. -E Ciuleanu,X. Yu,A. Pluzanski,A. Nagrial,L. Havel,R. D. Kowalyszyn,C. A. Valette,J. R. Brahmer,M. Reck,S. S. Ramalingam, L. Zhang,I. Ntambwe, S. K. Rabindran,F. E. Nathan,D. Balli,Y. -L. Wu

ESMO OPENno. 6 (2023)

引用10浏览0WOS引用

1378P Efficacy and Safety of Tunlametinib (HL-085) Combined with Vemurafenib in Patients with Advanced BRAF V600-mutated Solid Tumors: A Multicenter, Phase I Study

Y-K. Shi,Y. Zheng,J. Chen,X. Yu,J. Fang, Y. Liu,D. Huang,T. Liu,H. Shen,S. Luo, H. Yu, Y. Cao,X. Zhang

Annals of Oncology (2023): S790

引用1浏览0引用

[A Case of Lung Adenocarcinoma with Markedly Elevated Amylase in Airway Secretions]

X Yu, J Su, B Wang, Y M Wang

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseasesno. 11 (2023): 1124-1126

引用0浏览0WOS引用

A Phase 1b Study of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions

B. Han,C. Zhou,W. Zheng,L. Wu,Z. Ma, H. Wang,X. Yu,G. Ding,D. Ma, L. Nie,Z. Zhang,X. Dong, Y. Shang,K. Tang,W. Zhang,J. Y. Hsu,Y. Jiang,Q. Zhao

JOURNAL OF THORACIC ONCOLOGY（2023）

引用2浏览0引用

EP11.02-03 First Line Sintilimab Plus Anlotinib Vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis

T. Chu,B. Han,Z. Yu,J. Wang,Y. Zhao, X. Mu,X. Yu, X. Shi,Q. Shi, M. Guan,C. Ding,N. Geng

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S616-S616

引用0浏览0引用

44P Exploratory Analysis of Peripheral Pharmacodynamic (PD) Biomarkers after Sitravatinib (sitra) and Tislelizumab (TIS) in Advanced Solid Tumors: SAFFRON-103

Y-L. Wu,B. Gao,J.C. Goh, J. Zhao,Z. Ma,J. Cui,X. Yu,D. Huang,D. Day,M. Voskoboynik,Q. Chu,Q. Zhou,M. Millward,H. Pan,M. Sun,Y. Peng, M. Liu,T. Tian, H. Li,J. Guo

Immuno-Oncology and Technology (2023): 100512

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn